Resumen acción ALKEM
Alkem Laboratories Limited, empresa farmacéutica, se dedica al desarrollo, fabricación y venta de productos farmacéuticos y nutracéuticos en la India y a escala internacional.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 1/6 |
| Past Performance | 5/6 |
| Financial Health | 6/6 |
| Dividends | 3/6 |
Competidores de Alkem Laboratories Limited
Historial de precios y rendimiento
| Historical stock prices | |
|---|---|
| Current Share Price | ₹4,735.20 |
| 52 Week High | ₹5,520.00 |
| 52 Week Low | ₹3,186.30 |
| Beta | 0.34 |
| 1 Month Change | -4.26% |
| 3 Month Change | -6.21% |
| 1 Year Change | 41.56% |
| 3 Year Change | 69.67% |
| 5 Year Change | 175.12% |
| Change since IPO | 242.71% |
Noticias y actualizaciones recientes
Alkem Laboratories Limited (NSE:ALKEM) Just Reported And Analysts Have Been Lifting Their Price Targets
Feb 13
Investors Appear Satisfied With Alkem Laboratories Limited's (NSE:ALKEM) Prospects
Jan 17Recent updates
Alkem Laboratories Limited (NSE:ALKEM) Just Reported And Analysts Have Been Lifting Their Price Targets
Feb 13Investors Appear Satisfied With Alkem Laboratories Limited's (NSE:ALKEM) Prospects
Jan 17We Think Alkem Laboratories (NSE:ALKEM) Can Manage Its Debt With Ease
Dec 27Is Alkem Laboratories (NSE:ALKEM) Using Too Much Debt?
Sep 14Alkem Laboratories (NSE:ALKEM) Is Paying Out A Larger Dividend Than Last Year
Aug 02Alkem Laboratories (NSE:ALKEM) Is Paying Out A Larger Dividend Than Last Year
Jul 07Alkem Laboratories (NSE:ALKEM) Is Paying Out A Larger Dividend Than Last Year
May 22We Think Alkem Laboratories (NSE:ALKEM) Can Stay On Top Of Its Debt
Mar 27Does Alkem Laboratories (NSE:ALKEM) Have A Healthy Balance Sheet?
Dec 26These 4 Measures Indicate That Alkem Laboratories (NSE:ALKEM) Is Using Debt Reasonably Well
Sep 20Alkem Laboratories' (NSE:ALKEM) Dividend Is Being Reduced To ₹4.00
Jul 27Alkem Laboratories' (NSE:ALKEM) Shareholders Will Receive A Smaller Dividend Than Last Year
Jul 13Does This Valuation Of Alkem Laboratories Limited (NSE:ALKEM) Imply Investors Are Overpaying?
Jun 11Does Alkem Laboratories (NSE:ALKEM) Have A Healthy Balance Sheet?
May 23Does This Valuation Of Alkem Laboratories Limited (NSE:ALKEM) Imply Investors Are Overpaying?
Mar 06Does Alkem Laboratories (NSE:ALKEM) Have A Healthy Balance Sheet?
Feb 21Alkem Laboratories (NSE:ALKEM) Is Paying Out A Larger Dividend Than Last Year
Feb 08Should You Be Adding Alkem Laboratories (NSE:ALKEM) To Your Watchlist Today?
Jan 09Does This Valuation Of Alkem Laboratories Limited (NSE:ALKEM) Imply Investors Are Overpaying?
Nov 30Here's Why Alkem Laboratories (NSE:ALKEM) Can Manage Its Debt Responsibly
Nov 17I Built A List Of Growing Companies And Alkem Laboratories (NSE:ALKEM) Made The Cut
Sep 07Here's Why Alkem Laboratories Limited's (NSE:ALKEM) CEO May Deserve A Raise
Aug 20Alkem Laboratories (NSE:ALKEM) Is Increasing Its Dividend To ₹5.00
Aug 03Is Alkem Laboratories (NSE:ALKEM) Using Too Much Debt?
Jul 19Does This Valuation Of Alkem Laboratories Limited (NSE:ALKEM) Imply Investors Are Overpaying?
Jul 01Do Alkem Laboratories's (NSE:ALKEM) Earnings Warrant Your Attention?
May 25What Kind Of Investors Own Most Of Alkem Laboratories Limited (NSE:ALKEM)?
Mar 17Why Dividend Hunters Love Alkem Laboratories Limited (NSE:ALKEM)
Mar 04Alkem Laboratories Limited (NSE:ALKEM) Insiders Have Been Selling
Feb 19Do Alkem Laboratories's (NSE:ALKEM) Earnings Warrant Your Attention?
Feb 07Alkem Laboratories (NSE:ALKEM) Could Be A Buy For Its Upcoming Dividend
Feb 07Rentabilidad de los accionistas
| ALKEM | IN Pharmaceuticals | Mercado IN | |
|---|---|---|---|
| 7D | -3.6% | -2.1% | -0.03% |
| 1Y | 41.6% | 57.5% | 46.9% |
Rentabilidad frente al sector: ALKEM obtuvo unos resultados inferiores a los del sector Indian Pharmaceuticals , que el año pasado arrojó un rendimiento del 66.4%.
Rentabilidad vs. Mercado: ALKEM obtuvo unos resultados inferiores a los del mercado Indian, que fue del 48.2% el año pasado.
Volatilidad de los precios
| ALKEM volatility | |
|---|---|
| ALKEM Average Weekly Movement | 4.1% |
| Pharmaceuticals Industry Average Movement | 5.9% |
| Market Average Movement | 6.8% |
| 10% most volatile stocks in IN Market | 10.1% |
| 10% least volatile stocks in IN Market | 4.2% |
Precio estable de las acciones: ALKEM no ha tenido una volatilidad de precios significativa en los últimos 3 meses.
Volatilidad a lo largo del tiempo: La volatilidad semanal de ALKEM (3%) se ha mantenido estable durante el año pasado.
Acerca de la empresa
| Fundada | Empleados | CEO | Página web |
|---|---|---|---|
| 1973 | 16,871 | Vikas Gupta | www.alkemlabs.com |
Alkem Laboratories Limited, empresa farmacéutica, se dedica al desarrollo, la fabricación y la venta de productos farmacéuticos y nutracéuticos en la India y a escala internacional. La empresa ofrece genéricos de marca, medicamentos genéricos, ingredientes farmacéuticos activos y biosimilares, y nutracéuticos en áreas terapéuticas agudas y crónicas que comprenden antiinfecciosos, dermatología, cardiología, respiratorio, gastrointestinal, sistema nervioso central, urología y ginecología, así como vitaminas, minerales y nutrientes; y productos analgésicos, antidiabéticos y de neurología. Alkem Laboratories Limited se constituyó en 1973 y tiene su sede en Bombay (India).
Resumen de fundamentos de Alkem Laboratories Limited
| Estadísticas fundamentales de ALKEM | |
|---|---|
| Capitalización bursátil | ₹566.16b |
| Beneficios(TTM) | ₹15.73b |
| Ingresos (TTM) | ₹126.34b |
36.0x
Ratio precio-beneficio (PE)4.5x
Ratio precio-ventas (PS)¿Está ALKEM sobrevalorada?
Ver valor justo y análisis de valoraciónBeneficios e Ingresos
| Cuenta de resultados (TTM) de ALKEM | |
|---|---|
| Ingresos | ₹126.34b |
| Coste de los ingresos | ₹52.00b |
| Beneficio bruto | ₹74.35b |
| Otros gastos | ₹58.62b |
| Beneficios | ₹15.73b |
Últimos beneficios comunicados
Dec 31, 2023
Próxima fecha de beneficios
n/a
| Beneficios por acción (BPA) | 131.58 |
| Margen bruto | 58.85% |
| Margen de beneficio neto | 12.45% |
| Ratio deuda/patrimonio | 14.1% |
¿Cómo se ha desempeñado ALKEM a largo plazo?
Ver rendimiento histórico y comparativa